Treatment retention with risperidone long-acting injection: 24-month results from the electronic schizophrenia treatment adherence registry (e-STAR) in six countries

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 501-509

  Peuskens, J ^a   Olivares, J M ^b   Pecenak, J ^c   Tuma, I ^d   Bij De Weg, H ^e   Eriksson, L ^f   Resseler, S ^g   Akhras, K ^h   Jacobs, A ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Hospital Meixoeiro Complejo   (Spain)

^c UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^d FNSP Hradec Kralove ^*  (Slovakia)

^e Division 'Meervoudige Zorg'   (Netherlands)

^f SU Östra RPV   (Sweden)

^g SGS Medisearch International NV   (Belgium)

^h JOHNSON AND JOHNSON   (United States)

Author keywords

Acting injection; Hospitalization; Observational study; Risperidone long; Schizophrenia; Treatment discontinuation

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; BREAST DISEASE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENITAL SYSTEM DISEASE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REGISTER; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; REGISTRIES; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS;

EID: 76949089882     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903488670     Document Type: Article

References (27)

1. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003;64(Suppl 16):24-33
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: 1209-1223
3. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17:235-244
4. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67 (Suppl 5):3-8
5. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-267
6. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66
7. Schooler NR. Relapse and rehospitalization: comparing oral and depot anti-psychotics. J Clin Psychiatry 2003;64(Suppl 16):14-17
8. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: Place in therapy. Drugs 1994;47:741-743
9. Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat 2007;3: E-pub
10. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-analysis of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179:290-299
11. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, deport intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004;14:87-92
12. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risper-idone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132
13. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64:1250-1257
14. Lasser RA, Bossie CA, Gharabawi GM, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219-225
15. Mohl A, Westlye S, Opjordsmoen S, et al. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 2005;19:22-31
16. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-296
17. Olivares JM, Rodriguez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risper-idone in patients with schizophrenia. A 12-and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53
18. Guy W. Clinical global impression. In: Rush AJ, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, 2000:100-102
19. Endicott J, Spitzer J, Fleiss J, et al. The Global Assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771
20. Niaz OS, Haddad PM. Thirty-five months experience or risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007;116:36-46
21. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006;114:14-20
22. Taylor DM, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 2008; e-pub
23. Taylor D. Risperidone long-acting injection in practice-more questions than answers. Acta Psychiatr Scand 2006;114:1-2
24. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21
25. Beauclair L, Chue P, McCormick J, et al. Impact of risperidone long-acting injectable on hospitalization and medication use in Canadian patients with schizophrenia. J Med Econ 2007;10:427-442
26. Chue P, Llorca P, Duchesne I, Leal A, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Applied Res 2005;5:266-274
27. Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 2009 E-pub